Dei Biopharma: $50 HIV Drug Lenacapavir Production in Uganda
Dei Biopharma is set to revolutionize HIV treatment access.The Ugandan firm plans to manufacture the primary_keyword, lenacapavir, for less than $50 annually, a staggering price reduction compared to the current market. This move directly confronts the challenge of expensive drugs, aiming to make treatment broadly available across developing nations. This initiative is a bold step in global health, especially for patients who have traditionally faced critically important secondary_keyword barriers.Dei Biopharma’s plans, reported by News Directory 3, could offer the first complete treatment option in africa. Their goal is to launch the drug within the next 18 months. Discover what’s next as this biotech company strives to lead the charge.
Ugandan Firm Aims to Produce Affordable HIV Treatment for Developing Nations
KAMPALA, Uganda – Dei Biopharma, a biotechnology company based in Uganda, announced plans to manufacture active pharmaceutical ingredients for patented drugs. The initial focus is on a newly approved HIV treatment, currently priced at tens of thousands of dollars annually.
Dei Biopharma intends to produce Lenacapavir (Yeztugo), an HIV-1 capsid inhibitor developed by Gilead Sciences. The U.S. Food and Drug Management approved the drug on June 18, 2025.
While the current market price is $28,000 per year, Dei Biopharma stated it aims to supply the same product to all Least developed Countries (LDCs) for less than $50. The company announced its plans in a press release on June 22.
According to Dei BioPharma, the move will provide the first complete HIV treatment option in africa. The company stated that high costs currently make treatments unaffordable, despite HIV posing a serious threat to the continent.
The company plans to launch the new drug within 18 months. Dei Biopharma also intends to expand its API manufacturing to include similar, expensive, and urgent products. The goal is to serve developing countries, positioning itself as the first company worldwide to do so.
Uganda is classified as a Least Developed Country (LDC) under the United Nations’ TRIPS agreement until 2034. This status allows the nation to produce generic versions of patented drugs for domestic use and export to other LDCs.
The announcement follows repeated calls from global health advocates, including Winnie Byanyima, Executive Director of UNAIDS, to address the high cost of essential medicines in developing nations.
Byanyima has frequently criticized pharmaceutical companies for setting high prices, arguing that these costs create barriers to access and worsen health inequalities, notably for life-saving treatments like those for HIV.
“UNAIDS has seen research that lenacapavir can be produced for just $40 per person per year, falling to $25 within a year of roll out. It is indeed beyond comprehension how Gilead can justify a price of $28,218. If this game-changing medicine remains unaffordable, it will change nothing. I urge Gilead to do the right thing. drop the price,expand production,and ensure the world has a shot at ending AIDS,” said UNAIDS Executive Director Byanyima.